TRAX (First Tracks Biotherapeutics) OCF Margin %: 0.00% (As of Dec. 2024)


TRAX First Tracks Biotherapeutics Inc TRAX
12 GF Score
Price $36.24
! 3 Warning Signs
View Full Analysis

What is First Tracks Biotherapeutics OCF Margin %?

First Tracks Biotherapeutics TRAX +11.85% 12 OCF Margin % is 0.00% as of Dec. 2024. GuruFocus rates TRAX with a GF Score™ of 12/100. The stock has 3 warning signs investors should review. Among 950 Biotechnology companies, First Tracks Biotherapeutics ranks worse than 105263.05% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. First Tracks Biotherapeutics's Cash Flow from Operations for the six months ended in Dec. 2024 was $-125.81 Mil. First Tracks Biotherapeutics's Revenue for the six months ended in Dec. 2024 was $0.00 Mil. Therefore, First Tracks Biotherapeutics's OCF Margin % for the quarter that ended in Dec. 2024 was 0.00%.

As of today, First Tracks Biotherapeutics's current OCF Yield % is -9.95%.

The historical rank and industry rank for First Tracks Biotherapeutics's OCF Margin % or its related term are showing as below:


TRAX's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -65.71
* Ranked among companies with meaningful OCF Margin % only.

First Tracks Biotherapeutics OCF Margin % Related Terms

First Tracks Biotherapeutics OCF Margin % Historical Data

* Premium members only.

The historical data trend for First Tracks Biotherapeutics's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

First Tracks Biotherapeutics OCF Margin % Chart

First Tracks Biotherapeutics Annual Data
Trend Dec23 Dec24
OCF Margin %
0.00 0.00

First Tracks Biotherapeutics Semi-Annual Data
Dec23 Dec24
OCF Margin % 0.00 0.00
TRAX
12GF Score
First Tracks Biotherapeutics Inc TRAX
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

First Tracks Biotherapeutics OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

First Tracks Biotherapeutics's OCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-125.806/0
= %

First Tracks Biotherapeutics's OCF Margin for the quarter that ended in Dec. 2024 is calculated as

OCF Margin=Cash Flow from Operations (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=-125.806/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
First Tracks Biotherapeutics (TRAX) has a OCF Margin % of 0.00% as of Dec. 2024. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on First Tracks Biotherapeutics and its competitors. According to the industry distribution chart, First Tracks Biotherapeutics ranks #999999 out of 950 companies in the Biotechnology industry.
Is First Tracks Biotherapeutics' OCF Margin % too high?
First Tracks Biotherapeutics' current OCF Margin % is 0.00%. Based on the distribution chart, First Tracks Biotherapeutics ranks #999999 out of 950 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, First Tracks Biotherapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does First Tracks Biotherapeutics' OCF Margin % compare to ALT and RGNX?
According to the Biotechnology industry distribution chart, First Tracks Biotherapeutics ranks #999999 out of 950 companies for OCF Margin %. This places First Tracks Biotherapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on First Tracks Biotherapeutics and its competitors. First Tracks Biotherapeutics's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is First Tracks Biotherapeutics stock overvalued right now?
First Tracks Biotherapeutics (TRAX) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. First Tracks Biotherapeutics' overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For First Tracks Biotherapeutics (TRAX), the current OCF Margin % is 0.00% as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

First Tracks Biotherapeutics Business Description

Other Exchanges B43:Germany
Address 10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
12GF Score

Get the complete analysis for TRAX

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$36.24
Price